✦ LIBER ✦

Coagulation disorders in cancer II. multiple myeloma

✍ Scribed by Julio Sanchez-Avalos; Bernadette C. F. Soong; Sherwood P. Miller

Publisher: John Wiley and Sons
Year: 1969
Tongue: English
Weight: 969 KB
Volume: 23
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(196906)23:6<1388::aid-cncr2820230621>3.0.co;2-g

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cancer in persons with inherited blood c

Cancer in persons with inherited blood coagulation disorders

✍ Walter B. Forman 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

Coagulation disorders in cancer. III. Fi

Coagulation disorders in cancer. III. Fibrinolysis and inhibitors

✍ Bernadette C. F. Soong; Sherwood P. Miller 📂 Article 📅 1970 🏛 John Wiley and Sons 🌐 English ⚖ 738 KB

I n a group of 100 unselected patients with disseminated malignancies, marked disturbances i n the coagulation and fibrinolytic systems were found. Mean silicone coagulation time was shortened, and fibrinogen levels were markedly elevated. Fibrinolysis activation, as manifested by plasma clot lysis,

Genetic studies in multiple myeloma. II.

Genetic studies in multiple myeloma. II. Immunoglobulin allotype associations

✍ Stephen H. Leech; Rebecca Brown; Moses S. Schanfield 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

A weakly positive but statistically significant association between HLA-Cw5 and myeloma has been reported in black patients. The authors attempted to determine whether immunoglobulin allotypes of the Cm series demonstrate any such association. They were identified in the sera of 29 black patients an

Phase II trial of amsacrine in patients

Phase II trial of amsacrine in patients with multiple myeloma

✍ Greipp, Philip R. ;Coleman, Morton ;Anderson, Keaven ;McIntyre, O. Ross 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Seventy-four previously treated patients with multiple myeloma were treated with Amsacrine (m-AMSA) 120 mg/m2 every 3 weeks. A good response was observed in two patients (3%), and improvement was seen in three patients (4%). Severe toxicity was observed in 33% of patients who received three or more

Multiple myeloma, leukemia, and cancer o

Multiple myeloma, leukemia, and cancer of the ovary in cosmetologists and hairdressers

✍ Mr. J. J. Spinelli; R. P. Gallagher; P. R. Band; W. J. Threlfall 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB 👁 2 views

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat